Fennec Pharmaceuticals, Inc. (FENC)
12.76
+1.14
(+9.81%)
USD |
NASDAQ |
Nov 16, 16:00
12.58
-0.18
(-1.41%)
After-Hours: 20:00
Fennec Pharmaceuticals Enterprise Value : 400.66M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 400.66M |
| November 13, 2026 | 360.51M |
| November 12, 2026 | 335.16M |
| November 11, 2026 | 326.00M |
| November 10, 2026 | 323.89M |
| November 09, 2026 | 332.69M |
| November 06, 2026 | 296.78M |
| November 05, 2026 | 281.98M |
| November 04, 2026 | 315.79M |
| November 03, 2026 | 328.12M |
| November 02, 2026 | 322.48M |
| October 30, 2026 | 311.92M |
| October 29, 2026 | 336.92M |
| October 28, 2026 | 334.10M |
| October 27, 2026 | 325.30M |
| October 26, 2026 | 308.75M |
| October 23, 2026 | 306.28M |
| October 22, 2026 | 314.73M |
| October 21, 2026 | 316.85M |
| October 20, 2026 | 319.66M |
| October 19, 2026 | 312.97M |
| October 16, 2026 | 302.76M |
| October 15, 2026 | 315.79M |
| October 14, 2026 | 302.76M |
| October 13, 2026 | 309.80M |
| Date | Value |
|---|---|
| October 12, 2026 | 328.82M |
| October 09, 2026 | 328.47M |
| October 08, 2026 | 325.65M |
| October 07, 2026 | 316.14M |
| October 06, 2026 | 315.79M |
| October 05, 2026 | 325.30M |
| October 02, 2026 | 310.51M |
| October 01, 2026 | 315.09M |
| September 30, 2026 | 326.36M |
| September 29, 2026 | 337.12M |
| September 28, 2026 | 342.37M |
| September 25, 2026 | 330.29M |
| September 24, 2026 | 330.81M |
| September 23, 2026 | 326.96M |
| September 22, 2026 | 344.48M |
| September 21, 2026 | 340.97M |
| September 18, 2026 | 330.81M |
| September 17, 2026 | 336.42M |
| September 16, 2026 | 328.36M |
| September 15, 2026 | 331.51M |
| September 14, 2026 | 334.32M |
| September 11, 2026 | 342.72M |
| September 10, 2026 | 354.64M |
| September 09, 2026 | 366.90M |
| September 08, 2026 | 394.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.321B |
| Alnylam Pharmaceuticals, Inc. | 20.79B |
| Anika Therapeutics, Inc. | 154.24M |
| Savara, Inc. | 818.43M |
| Arrowhead Pharmaceuticals, Inc. | 6.454B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.64M |
| Revenue (Quarterly) | 19.61M |
| Total Expenses (Quarterly) | 14.97M |
| EPS Diluted (Quarterly) | 0.1219 |
| Gross Profit Margin (Quarterly) | 95.73% |
| Profit Margin (Quarterly) | 23.66% |
| Earnings Yield | 0.13% |
| Operating Earnings Yield | 0.72% |
| Normalized Earnings Yield | 0.4867 |